MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
CRISPR Therapeutics AG Operating Cash Flow 2011-2026 | CRSP
Annual Operating Cash Flow CRISPR Therapeutics AG
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -345 M | -143 M | -260 M | -496 M | 539 M | -238 M | 56.7 M | -96.2 M | -70.1 M | -52.9 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 539 M | -496 M | -111 M |
Quarterly Operating Cash Flow CRISPR Therapeutics AG
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -53.9 M | - | - | - | 110 M | - | - | - | 8.8 M | - | -382 M | -277 M | -135 M | - | 625 M | 706 M | -101 M | - | -157 M | -81.5 M | -52.2 M | - | 53.3 M | -80.1 M | -43.7 M | - | -67.9 M | -47.9 M | -22.7 M | - | -55.3 M | -39.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 706 M | -382 M | -4.7 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-8.24 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-2.67 M | - | 1.35 % | $ 17.8 M |  China |
 |
Amphastar Pharmaceuticals
AMPH
|
156 M | $ 16.89 | -2.37 % | $ 789 M |  USA |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | USA |
 |
Compugen Ltd.
CGEN
|
31.6 M | $ 2.85 | -5.94 % | $ 266 M |  Israel |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M | China |
 |
Coherus BioSciences
CHRS
|
-139 M | $ 1.58 | -3.37 % | $ 185 M | USA |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B | France |
 |
AstraZeneca PLC
AZN
|
14.6 B | - | - | $ 96.9 B |  Britain |
 |
Arcturus Therapeutics Holdings
ARCT
|
-74.3 M | $ 7.46 | -4.73 % | $ 204 M | Israel |
 |
Athira Pharma
ATHA
|
-45.7 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-24.5 M | - | 0.74 % | $ 768 M | Israel |
 |
Galera Therapeutics
GRTX
|
-6.05 M | - | -32.59 % | $ 7.61 M | USA |
 |
Eton Pharmaceuticals
ETON
|
10.5 M | $ 29.73 | -0.77 % | $ 800 M | USA |
 |
Exelixis
EXEL
|
884 M | $ 50.09 | -1.98 % | $ 13.6 B | USA |
 |
Midatech Pharma plc
MTP
|
-5.59 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Fortress Biotech
FBIO
|
-65.8 M | $ 2.47 | 7.39 % | $ 68.9 M | USA |
|
Forte Biosciences
FBRX
|
-50.9 M | $ 22.53 | -5.97 % | $ 292 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
-12.5 M | $ 9.51 | 2.92 % | $ 272 M | USA |
 |
AbCellera Biologics
ABCL
|
-131 M | $ 4.03 | -8.52 % | $ 1.2 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
-284 M | $ 1.57 | -1.26 % | $ 418 M | Britain |
 |
BioNTech SE
BNTX
|
456 M | $ 88.94 | -3.32 % | $ 21.5 B | Germany |
 |
Checkmate Pharmaceuticals
CMPI
|
-53.7 M | - | - | $ 231 M | USA |
 |
Galectin Therapeutics
GALT
|
-23.9 M | $ 2.22 | -5.74 % | $ 142 M | USA |
 |
Gilead Sciences
GILD
|
10 B | $ 129.56 | -1.9 % | $ 161 B | USA |
 |
Genmab A/S
GMAB
|
7.77 B | $ 26.79 | -0.41 % | $ 1.73 B |  Danmark |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.95 M | $ 3.36 | -5.62 % | $ 5.53 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-8.47 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
Grifols, S.A.
GRFS
|
902 M | $ 7.67 | -1.6 % | $ 5.21 B |  Spain |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
-10.4 M | $ 0.72 | -1.76 % | $ 32.9 M | Israel |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Esperion Therapeutics
ESPR
|
-13.1 M | $ 3.13 | 0.32 % | $ 651 M | USA |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
-38.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
-116 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-5.62 M | $ 21.66 | 0.42 % | $ 2.76 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |